Compare Medpace Holdings Inc (MEDP) vs Novagold Resources Inc. (NG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Novagold Resources Inc. — how do they compare? Medpace Holdings Inc trades at $616.98 (market cap $17.21B), while Novagold Resources Inc. trades at $6.37 (market cap $2.73B). The key difference: Medpace Holdings Inc is far larger — about 6.3× Novagold Resources Inc.'s market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Novagold Resources Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Novagold Resources Inc. for 0 Days on average.
| MEDP | NG | |
|---|---|---|
Market Cap | $17.21B | $2.73B |
Volume | 311,245 | 6,599,188 |
Sector | Health | Basic Materials |
52-Week High | $630.19 | $14.20 |
52-Week Low | $393.42 | $5.18 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $16.83B | $2.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $609.89, down 1.64% today, with a bullish technical signal and strong support near $606. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue grew to $2.53B in 2025, with a net income margin of 17.67%. Recent news highlights CEO stock sales and institutional position adjustments.
Outlook remains positive with a consensus price target of $620.44, offering modest upside. Key risks include high valuation multiples and insider selling. Earnings growth and sector demand are primary catalysts, but investor caution is warranted given elevated P/E and P/B ratios.
NovaGold Resources (NG) trades at $6.63, down 1.49% today, as the company navigates its development phase for the Donlin Gold project. The stock shows mixed earnings performance with recent quarterly losses but beats expectations in two of the last four quarters. Financials reveal negative profitability metrics with ROE at -32.81% and net income of -$94.66M for 2025, though cash flow remains positive due to financing activities. Recent news highlights the company's move to acquire full ownership of Donlin Gold, a major Alaska gold project.
The outlook for NG hinges on successful development of Donlin Gold, with 100% analyst buy ratings signaling strong Wall Street confidence. However, significant execution risks exist given negative earnings and substantial capital requirements. Investors face volatility from gold price fluctuations and project development timelines, making this suitable for those with high risk tolerance seeking exposure to a major gold development story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Novagold Resources Inc.
NovaGold Resources Inc. is a mineral exploration and development company that holds a majority interest in the Donlin Gold project, an undeveloped gold deposit in Alaska.
Read more on NG →
